Compare Quest Diagnostics Inc (DGX) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Tesla, Inc. — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while Tesla, Inc. trades at $382.7 (market cap $1.48T). The key difference: Tesla, Inc. is far larger — about 58.1× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Tesla, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Tesla, Inc. for 88 Days on average.
| DGX | TSLA | |
|---|---|---|
Market Cap | $25.48B | $1.48T |
Volume | 941,866 | 28,215,427 |
Sector | Health | Consumer Cyclical |
52-Week High | $247.45 | $489.88 |
52-Week Low | $173.49 | $298.16 |
Typical Hold Time | 56 Days | 88 Days |
Enterprise Value | $31.23B | $1.45T |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.68% with strong year-to-date performance driven by organic growth and advanced diagnostics adoption. The company has consistently beaten earnings expectations in recent quarters with Q2 2026 EPS of $3.12 exceeding estimates. Technical indicators show a bearish bias while fundamentals remain solid with 9.19% net margin and 14.35% ROE. Recent developments include a partnership with Apple Health app and positive clinical study results.
DGX presents a mixed outlook with strong fundamental performance offset by technical weakness and regulatory headwinds. The 38% upside to consensus price target of $250 offers potential, but Medicare reimbursement cuts and bearish technical signals warrant caution. Growth in consumer testing and strategic partnerships provide catalysts, though execution risks and debt levels require monitoring.
Tesla trades at $375.03, down 0.68% on the day, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported Q2 2026 earnings miss ($0.33 actual vs. $0.50 expected) but beat expectations in the previous two quarters. Revenue declined to $94.83B in 2025 with net income margin compressing to 4%. Recent news highlights regulatory approval for driver assistance software in Europe and a potential cheaper EV launch.
Tesla faces near-term headwinds from slowing auto growth and elevated valuations (P/E 347), but long-term optimism centers on autonomous driving and energy segments. Analyst consensus price target of $441.36 suggests 18% upside, though execution risks and competition remain key concerns for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
